

December 16, 2005

Dainippon Sumitomo Pharma Co., Ltd.  
Sumitomo Chemical Co., Ltd.

**Dainippon Sumitomo Pharma and Sumitomo Chemical File Countersuit Against Pfizer**

Dainippon Sumitomo Pharma and Sumitomo Chemical filed a countersuit with the Tokyo District Court on December 15, 2005 with regard to the product Amlodin (generic name: amlodipine besilate) manufactured and sold by Dainippon Sumitomo Pharma, for which the licensor, Pfizer (Pfizer Ltd. and Pfizer Corp. collectively), filed a lawsuit against the two companies on November 17, 2005, claiming damages from patent infringement and calling for the immediate cessation of the manufacture and sales of Amlodin by Dainippon Sumitomo Pharma. The countersuit seeks to have their legitimate positions under the license agreement for Amlodin affirmed in court.

Both Dainippon Sumitomo Pharma and Sumitomo Chemical are confident that the filing of this countersuit will establish the legitimacy of their position under the relevant terms of the license agreement.

Upon filing the countersuit, Dainippon Sumitomo Pharma and Sumitomo Chemical withdrew their previous lawsuit filed on November 1, 2005 because the claims were the same as those of their newly filed countersuit. Pfizer also had earlier withdrawn its two preliminary injunction petitions filed in October 2005.